SCHEMBL10186396

SCHEMBL10186396

CCCCOC(=O)c1ccc(O[C@H]2CC[C@@H](CC(=O)OC)CC2)c(F)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.40
TDP1 Q9NUW8 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
MAPK1 P28482 4/20 0.37
CYP3A4 P08684 2/20 0.37
TP53 P04637 1/20 0.37
ALDH1A1 P00352 6/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 2/20 0.36
ESR1 P03372 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 3/20 0.34
HPGD P15428 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10186399 0.84 CRBN (0.41) TSHRTDP1L3MBTL1MAPK1CYP3A4
SCHEMBL10186120 0.84 MEN1 (0.42) TSHRL3MBTL1MAPK1CYP3A4ALDH1A1
SCHEMBL10148321 0.82 FFAR4 (0.37) PDE4APDE4BPDE4CPDE4D
SCHEMBL10148325 0.82 ACACB (0.38) HPGD
SCHEMBL10184863 0.82 TSHR (0.43) TSHRTDP1L3MBTL1MAPK1CYP3A4
SCHEMBL10185041 0.82 TSHR (0.43) TSHRTDP1L3MBTL1MAPK1CYP3A4
SCHEMBL13117542 0.79 LMNA (0.51) TSHRMAPK1CYP3A4ALDH1A1HSD17B10
SCHEMBL26770212 0.70 CYP1A2 (0.40) TDP1L3MBTL1ALDH1A1SMN1; SMN2MEN1
SCHEMBL10148299 0.69 HRH3 (0.45)
SCHEMBL10148300 0.69 PDE4D (0.41) MAPK1ALDH1A1LMNAMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 TSHR 4189/4885TDP1 2744/4885L3MBTL1 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.